Control Bionics Ltd. engages in the manufacture, design, and sale of wireless wearable electromyography (EMG) based augmentative and alternative communication (AAC) technology. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development, commercialization, and sale of assistive communications technology systems within the disability sector. The company assists patients whose ability to communicate verbally or through text and social media is compromised by illnesses, such as motor neuron disease and amyotrophic lateral sclerosis. Its NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as Electromyography output. This output is then sent wirelessly through the NeuroNode to a personal computer, enabling speech and other computer-controlled functions, such as email and texting. Its core systems include NeuroNode Trilogy, NeuroNode Duo and Eye-gaze Duo. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven like a mouse, and the NeuroNode acts as like the mouse button.
Control Bionics (ASX: CBL)
- Home
- Control Bionics (ASX: CBL)
Here are the latest articles on Control Bionics (ASX: CBL)
Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode
August 19, 2024
The Centers for Medicare & Medicaid Services has approved a new Healthcare Common Procedure Coding System code for the NeuroNode, patent technology by Control Bionics (ASX: CBL). This approval, effective from 1 October 2024, introduces a reimbursement rate of US$4,300 for the NeuroNode, a significant enhancement from the previous reimbursement conditions. Control Bionics is a
TGA approves Control Bionic’s autonomous wheelchair for commercial sales after NDIS delays
June 20, 2024
So you’ve seen self-driving cars and drones, now gear up for an autonomous wheelchair that dispels the need for joysticks. In wheelchair users, atrophying muscles can make it challenging to use the joystick properly, thus losing control of their wheelchair. That’s where digitising the experience further helps. Medical device company Control Bionics (ASX: CBL)’s autonomous
They see me rollin, they lovin: Control Bionics receives $577k grant from the ALS association to develop self-driving wheelchairs
January 24, 2024
If you thought only cars could be autonomous (hey, Tesla), think again. Medical device company Control Bionics (ASX: CBL) has wheeled the technology into autonomous wheelchairs, ensuring people with Amyotrophic Lateral Sclerosis (ALS)—a motor neuron disease—live a better, “freer” life. In support of that, the Company’s wholly-owned US subsidiary has secured a research grant of
Control Bionics and Deakin Uni collab will soon launch the world’s first mind-controlled wheelchair
April 19, 2023
For wheelchair users, comfort, safety and ease of use would be the top three priority features when it comes to finding the perfect wheelchair. Now, imagine if there soon will exist a groundbreaking feature that will take wheelchair tech to the next level; that is independence. Applications of this feature are already visible on the
Control Bionics to grow accessibility tech for the disabled with $15m IPO
November 25, 2020
Technology company, Control Bionics Limited (Proposed ASX: CBL) are one of the latest medtech companies looking to list on the exchange next month. The company is looking to raise $15m by November 25 at an offer price of $0.60 per share, giving the company an indicative market capitalization at the offer price of $50m. The
Recent Articles
